Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501406 | 0.82 | ALDH1A1 (0.52) | TTRALBMEN1KMT2AALDH1A1 | |
| SCHEMBL200313 | 0.82 | TTR (0.52) | TTRALBMEN1KMT2AALDH1A1 | |
| SCHEMBL1004620 | 0.82 | ALDH1A1 (0.52) | TTRALBMEN1KMT2AALDH1A1 | |
| SCHEMBL504640 | 0.82 | TTR (0.52) | TTRALBMEN1KMT2AALDH1A1 | |
| SCHEMBL16956614 | 0.76 | ALDH1A1 (0.36) | ALDH1A1MAPK1 | |
| SCHEMBL16951266 | 0.76 | ALDH1A1 (0.36) | ALDH1A1MAPK1 | |
| SCHEMBL16950941 | 0.73 | TTR (0.44) | TTRALBMEN1KMT2AMAOA | |
| SCHEMBL1979138 | 0.73 | TTR (0.40) | TTRALBMEN1KMT2AGRM5 | |
| SCHEMBL23224112 | 0.73 | ALDH1A1 (0.45) | TTRALBMEN1KMT2AALDH1A1 | |
| SCHEMBL249769 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130925-A1 | METHODS FOR TREATING CANCER | GENESIS MOLECULAR AI INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4696680-A1 | DUAL-FUNCTIONAL TETRAZINE COMPOUNDS FOR VERSATILE RADIOLABELING WITH RADIOMETALS AND RADIOHALOGENS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Tetrakit Technologies ApS (DK) | 2026-02-18 | — | — | EP | disclosed |
| US-20260008782-A1 | HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | CONVELO THERAPEUTICS, INC. | 2026-01-08 | — | — | US | disclosed |
| US-12415795-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | NXERA PHARMA UK LIMITED (GB) | 2025-09-16 | — | — | US | disclosed |
| EP-4602031-A1 | METHODS FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2025-07-24 | — | — | US | disclosed |
| CN-119998288-A | Hydantoin modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119638633-A | Method for preparing pyridazinone compound and application thereof | 深圳市华先医药科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-12195449-B2 | 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof | BEIGENE, LTD. (KY) | 2025-01-14 | — | — | US | disclosed |
| EP-1556142-A2 | ALKYNE DERIVATIVES AS TRACERS FOR METABOTROPIC GLUTAMATE RECEPTOR BINDING | Merck & Co., Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040248981-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| WO-2004038374-A2 | ALKYNE DERIVATIVES AS TRACERS FOR METABOTROPIC GLUTAMATE RECEPTOR BINDING | MERCK & CO., INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| CN-1131856-C | Cyclothiocarbamate derivatives as progesterone receptor modulators | AMERICAN HOME PRODUCTS CORP. (US) | 2003-12-24 | — | — | CN | disclosed |
| US-20030092711-A1 | Contraceptives; hormone replacement therapy | WYETH LLC | 2003-05-15 | — | — | US | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
| US-6436929-B1 | 3,1-BENZOXAZINE-2-THIONES; CONTRACEPTION AND THE TREATMENT OF PROGESTERONE-RELATED MALADIES | WYETH | 2002-08-20 | — | — | US | disclosed |
| CN-1349516-A | Cyclothiocarbamate derivatives as progesterone receptor modulators | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092711-A1 | Contraceptives; hormone replacement therapy | PGR, GNRHR, GHRHR | TTR 1423/4885ALB 1564/4885MEN1 2137/4885 |
| US-20260008782-A1 | HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | SGMS1, MAG, SGMS2 | TTR 2959/4885ALB 4643/4885MEN1 2282/4885 |
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | TTR 1353/4885ALB 353/4885MEN1 2216/4885 |
| US-12415795-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM6, GRM2 | TTR 4338/4885ALB 4268/4885MEN1 4742/4885 |
| US-20040248981-A1 | Benzamidine derivatives | HABP2, F7, F2 | TTR 1283/4885ALB 339/4885MEN1 2207/4885 |
| US-20260130925-A1 | METHODS FOR TREATING CANCER | PIK3R1, PIK3R5, PIK3R2 | TTR 4680/4885ALB 4839/4885MEN1 3292/4885 |
| US-12195449-B2 | 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof | HIPK1, HIPK3, HIPK2 | TTR 4786/4885ALB 4648/4885MEN1 3338/4885 |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | TTR 4788/4885ALB 4645/4885MEN1 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.